SIRION Biotech collaborates with Sanofi to improve Adeno-Associated Virus Capsids

SIRION Biotech GmbH, which is a world leader in viral vector and genome-based delivery technologies for gene and cell therapy, in a recent announcement, has stated that it signed a collaboration agreement with Sanofi, which is a global biopharmaceutical company. The collaboration aims at providing improved tissue-selective adeno-associated Virus (AAV) vectors to bring an effective gene therapy-based treatment for disorders that primarily affect human organs.

AAV vectors which are said to be a promising and clinically validated gene delivery platform provides multiple advantages over other vectors. Sanofi and SIRION Biotech, along with the world's most renowned scientist Dirk Grimm in the field of AAV biology and application working at Heidelberg University Hospital in Germany, will combine their knowledge vector technology to create the next generation of AAV vectors.

This partnership will expand the toolbox of technologies in the most fascinating and emerging area of gene therapeutics. It will also help to develop virus-based vaccines and viral vector manufacturing sectors. It will also allow both the firms to address the unmet medical needs and open new frontiers in drug discovery in genomic medicine and gene therapy.